Study S003304

An Investigator- and Participant-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight

ClinicalTrials.gov record

Registration

Registration: NCT07499050
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 30
Start: 2026-03-30
Primary completion: 2027-01-09
Lead sponsor: Hoffmann-La Roche
Conditions: Healthy Volunteers; Overweight or Obesity
Interventions: DRUG:RO7795081; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Incidence, Severity, and Causal Relationship to Treatment of Adverse Events [Baseline to Safety Follow-Up (26 weeks)]
Incidence of Abnormal Clinical Laboratory Test Findings [Baseline to Safety Follow-Up (26 weeks)]
Incidence of Abnormal Vital Signs [Baseline to Safety Follow-Up (26 weeks)]
Incidence of Abnormal Electrocardiogram (ECG) Results [Baseline to Safety Follow-Up (26 weeks)]
Incidence of Abnormal Psychiatry Parameters [Baseline to Safety Follow-Up (26 weeks)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.